Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Forcing Bioasis to Answer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(132)
•••
Comment by emmitfitzhumeon Jan 16, 2023 6:41pm
90 Views
Post# 35226741

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to Answer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to AnswerAnd before anyone highlights to me the benefits we are receiving as a Biodexa shareholder, yeah, it is not lost on me that we will be getting Midatech assets.  And I’m sure they have a swell pipeline with wonderful assets, but they are already a Nasdaq listed company and as broke or more broke than we are. 

This whole concept of combing two wrongs to make a right seems rather clown world to me.

Furthermore, I am a Biosis investor because I was enamored with XB3 and the hope of getting drugs elegantly across the BBB to treat serious and debilitating CNS diseases.  I am not however interested in implanting pumps into children’s abdomens with catheters traversing to thier brain delivering toxic chemotherapy directly a tumor.  Calling these companies synergistic could be perhaps the biggest laugher of all.  Wouldn’t XB3 if it worked negate the needs for brute force drug delivery with mechanical pumps and neurosurgically implanted catheters?  Sorry, this is not cutting edge or revolutionary or anything like what I signed up to invest in when I bought Biosis shares….

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities